Mental Health

Kyle Detwiler, CEO of Clever Leaves, discusses his company’s donation of $1 million in medical-grade cannabis to research organizations for the purposes of advancing medical research.

Kelan Thomas, PharmD, MS, associate professor of clinical sciences at Touro University California College of Pharmacy, discusses common themes or key points being raised in the field of psychedelic medicine at recent conferences.

Kelan Thomas, PharmD, MS, associate professor of clinical sciences at Touro University California College of Pharmacy, discusses some best clinical practices for psychedelic-assisted therapy in terms of assessing pharmacological profile.

This is the first large-scale transdiagnostic study of objectively measured sleep and mental health.

Study indicates that women with trauma had greater white matter hyperintensities (WMH) than women without trauma, and the most common trauma associated with WMH was sexual violence.

Investigators reviewed 65 analyses published in the Journal of Affective Disorders showing that by mid-2020 signs were comparable to pre-COVID-19 levels.

Kelan Thomas, PharmD, MS, associate professor of clinical sciences at Touro University California College of Pharmacy, on his recent presentations at Insight 2021 and the virtual Sana Symposium on psychedelic adverse effects and drug-drug interactions.

Evidence of a causal relationship between the onset of allergic disease and mental health was limited, suggesting that the observational associations found were due to confounding or other forms of bias.

Individuals who are insulin-resistant are 2.66 times more likely to suffer from major depression than those who are not insulin-resistant.

Nathan Bryson, PhD, chief scientific officer of Field Trip Health, said the company's new psychedelic compound, FT-104, could have potential uses in the treatment of postpartum depression.

Common and debilitating, the mental health condition is often underdiagnosed and undertreated.

Paula Durlofsky, PhD, a writer for the American Psychological Association's Device Management and Digital Intelligence committee discusses how social media has impacted the mental health of health care professionals in recent years, including the COVID-19 Pandemic.

Walgreens Boots Alliance announces new mental health services including mental health first aid training, Walgreens Find Care, and more partnerships for other mental health resources.

Patients with bulimia may use different methods to get rid of calories and prevent weight gain, such as self-inducing vomiting on a regular basis.

Kelan Thomas, PharmD, MS, associate professor of clinical sciences at Touro University California College of Pharmacy, discusses potential drug-drug interactions with psilocybin, MDMA, and ketamine to consider outside of interactions with psychiatric medications.

Payton Nyquvest, CEO and founder of Numinus, said he believes psychedelic medicines will lead to a significant shift in the mental health treatment landscape in the next 3 to 5 years.

Kelan Thomas, PharmD, MS, associate professor of clinical sciences at Touro University California College of Pharmacy, discusses the situations in which serotonin syndrome may be an area of concern when treating patients on psychiatric medication with psychedelic medicine.

Study results shows that patients who have been diagnosed with the disease may face many challenges, which can increase anxiety or depression.

The #PizzaIsNotWorking campaign originated because free pizza or other mundane incentives do not adequately address the unrealistic expectations in pharmacies, which lead to an emphasis on metrics rather than patient safety.

Ismail Lourido Ali, the director and counsel of policy and advocacy at the Multidisciplinary Association for Psychedelic Studies (MAPS), discusses what MAPS is, and how MAPS is engaged with the field of psychedelic medicine and its use in health care.

Misconceptions about the diagnosis of attention-deficit hyperactivity disorder reduce the credibility of health care providers and delay or prevent treatment for patients suffering from this condition.

The efficacy of Latuda in schizophrenia and bipolar depression could be mediated through a combination of central dopamine D2 and serotonin type 2 receptor antagonism.

Stacy Miller, senior content management consultant for Wolters Kluwer Health, discusses how mental health in the United States could be improved by stronger connections between prescribers and pharmacists.

Kelsey Ramsden, CEO of Mind Cure Health, said research into the use of MDMA-assisted therapy could have a huge impact on the treatment of female hypoactive sexual desire disorder.

Michael Frank, CEO of Revive Therapeutics, and Derrick Welsh, COO of Psilocin Pharma, a division of Revive Therapeutics, discuss clinical research investigating novel treatment targets for psilocybin, such as treatment-resistant depression in patients with cancer.

Kelan Thomas, PharmD, MS, associate professor of clinical sciences at Touro University California College of Pharmacy, discusses key points to consider regarding co-administration of MDMA, psilocybin, and ketamine with psychiatric medications, such as SSRI or SNRI antidepressants.

Senator Scott Wiener, discusses the California Senate Bill 519 he co-authored, which is the first and most expansive psychedelic decriminalization bill to go through a state legislature.

Schizophrenia may result in some combination of hallucinations, delusions, and extremely disordered thinking and behavior.

Kelan Thomas, PharmD, MS, associate professor of clinical sciences at Touro University California College of Pharmacy, discusses potential adverse effects and drug-drug interactions with psilocybin, MDMA, and ketamine treatment.

There are several types of bipolar disorders, including mania or hypomania and depression.